Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

1 of 0 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

5(71.4%)

Phase 2

1(14.3%)

Phase 3

1(14.3%)

7Total

Phase 1(5)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07216443Phase 2Recruiting

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Role: lead

NCT05322850Phase 1Suspended

Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)

Role: collaborator

NCT05088356Phase 1Recruiting

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Role: collaborator

NCT05316701Phase 3Active Not Recruiting

Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Role: lead

NCT03802695Phase 1Recruiting

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Role: lead

NCT07346105Unknown

Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies

Role: lead

NCT04013685Phase 1Active Not Recruiting

Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Role: lead

NCT06900192Phase 1Not Yet Recruiting

A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis

Role: collaborator

All 8 trials loaded